Cargando…
Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors
Thousands of leprosy patients not only suffer from physical deformities, but also either have or have had hepatitis B virus (HBV) coinfection. Polymorphisms of the complement system modulate susceptibility to leprosy, but genetic susceptibility to past or present HBV infection is unknown. We used se...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904891/ https://www.ncbi.nlm.nih.gov/pubmed/33643280 http://dx.doi.org/10.3389/fimmu.2020.574457 |
_version_ | 1783655012612702208 |
---|---|
author | Boldt, Angelica Beate Winter Oliveira-Toré, Camila de Freitas Kretzschmar, Gabriela Canalli Weinschutz Mendes, Hellen Stinghen, Sérvio Túlio Andrade, Fabiana Antunes Bumiller-Bini, Valéria Gonçalves, Letícia Boslooper Braga, Anna Carolina de Moraes Stahlke, Ewalda von Rosen Seeling Velavan, Thirumalaisamy P. Thiel, Steffen de Messias-Reason, Iara José Taborda |
author_facet | Boldt, Angelica Beate Winter Oliveira-Toré, Camila de Freitas Kretzschmar, Gabriela Canalli Weinschutz Mendes, Hellen Stinghen, Sérvio Túlio Andrade, Fabiana Antunes Bumiller-Bini, Valéria Gonçalves, Letícia Boslooper Braga, Anna Carolina de Moraes Stahlke, Ewalda von Rosen Seeling Velavan, Thirumalaisamy P. Thiel, Steffen de Messias-Reason, Iara José Taborda |
author_sort | Boldt, Angelica Beate Winter |
collection | PubMed |
description | Thousands of leprosy patients not only suffer from physical deformities, but also either have or have had hepatitis B virus (HBV) coinfection. Polymorphisms of the complement system modulate susceptibility to leprosy, but genetic susceptibility to past or present HBV infection is unknown. We used sequencing and multiplex sequence-specific PCR to genotype 72 polymorphisms of seven genes (MBL2, FCN1, FCN2, FCN3, MASP1, MASP2, C3) encoding components of the lectin pathway, and two genes encoding complement receptors (CR1, VSIG4) in 190 patients, of which 74 were positive for HBsAg and/or anti-HBc (HBV+, 93.2% with a resolved infection) and 116 lepromatous patients, and 408 HBV-blood donors. In addition, we tested for levels of proteins of the lectin pathway. We found no difference between serum concentrations of mannan-binding lectin (MBL), MBL-associated serine proteins (MASP-1, MASP-2, MASP-3, MAp44), ficolin-3 (FCN-3), soluble complement receptor 1 (sCR1) and MBL mediated C4 activation, measured by ELISA or TRIFMA in up to 167 HBV+ and HBV− patients. Haplotypes lowering protein levels or encoding dysfunctional proteins increased susceptibility to HBV infection: MBL2*LYQC (OR = 3.4, p = 0.02), MASP1*AC_CC (OR = 4.0, p = 0.015) and MASP2*1C2-l (OR = 5.4, p = 0.03). Conversely, FCN1*3C2 haplotype, associated with higher gene expression, was protective (OR = 0.56, P = 0.033). Other haplotypes associated with HBV susceptibility were: MASP2*2B1-i (OR = 19.25, P = 0.003), CR1*3A (OR = 2.65, P = 0.011) and VSIG4*TGGRCG (OR = 12.55, P = 0.014). Some polymorphisms in ficolin genes associated with lower protein levels increased susceptibility to leprosy/HBV infection: FCN*1 (OR = 1.66, P = 0.029), FCN2*GGGCAC (OR = 6.73, P = 0.008), and FCN3*del_del_C (OR = 12.54, P = 0.037), and to lepromatous disease/HBV infection: FCN2*TA (OR = 2.5, P = 0.009), whereas FCN2*MAG was associated with increased FCN-2 expression and resistance against coinfection (OR = 0.29, P = 0.026). These associations were independent of demographic factors and did not increase susceptibility to leprosy per se, except MASP2*1C2-l. Associations for FCN2, FCN3, MASP1, MASP2, and VSIG4 variants were also independent of each other. In conclusion, polymorphisms compromising activation of the lectin pathway of complement increase susceptibility to HBV infection, with ficolin polymorphisms playing a major role in modulating the susceptibility among leprosy patients. |
format | Online Article Text |
id | pubmed-7904891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79048912021-02-26 Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors Boldt, Angelica Beate Winter Oliveira-Toré, Camila de Freitas Kretzschmar, Gabriela Canalli Weinschutz Mendes, Hellen Stinghen, Sérvio Túlio Andrade, Fabiana Antunes Bumiller-Bini, Valéria Gonçalves, Letícia Boslooper Braga, Anna Carolina de Moraes Stahlke, Ewalda von Rosen Seeling Velavan, Thirumalaisamy P. Thiel, Steffen de Messias-Reason, Iara José Taborda Front Immunol Immunology Thousands of leprosy patients not only suffer from physical deformities, but also either have or have had hepatitis B virus (HBV) coinfection. Polymorphisms of the complement system modulate susceptibility to leprosy, but genetic susceptibility to past or present HBV infection is unknown. We used sequencing and multiplex sequence-specific PCR to genotype 72 polymorphisms of seven genes (MBL2, FCN1, FCN2, FCN3, MASP1, MASP2, C3) encoding components of the lectin pathway, and two genes encoding complement receptors (CR1, VSIG4) in 190 patients, of which 74 were positive for HBsAg and/or anti-HBc (HBV+, 93.2% with a resolved infection) and 116 lepromatous patients, and 408 HBV-blood donors. In addition, we tested for levels of proteins of the lectin pathway. We found no difference between serum concentrations of mannan-binding lectin (MBL), MBL-associated serine proteins (MASP-1, MASP-2, MASP-3, MAp44), ficolin-3 (FCN-3), soluble complement receptor 1 (sCR1) and MBL mediated C4 activation, measured by ELISA or TRIFMA in up to 167 HBV+ and HBV− patients. Haplotypes lowering protein levels or encoding dysfunctional proteins increased susceptibility to HBV infection: MBL2*LYQC (OR = 3.4, p = 0.02), MASP1*AC_CC (OR = 4.0, p = 0.015) and MASP2*1C2-l (OR = 5.4, p = 0.03). Conversely, FCN1*3C2 haplotype, associated with higher gene expression, was protective (OR = 0.56, P = 0.033). Other haplotypes associated with HBV susceptibility were: MASP2*2B1-i (OR = 19.25, P = 0.003), CR1*3A (OR = 2.65, P = 0.011) and VSIG4*TGGRCG (OR = 12.55, P = 0.014). Some polymorphisms in ficolin genes associated with lower protein levels increased susceptibility to leprosy/HBV infection: FCN*1 (OR = 1.66, P = 0.029), FCN2*GGGCAC (OR = 6.73, P = 0.008), and FCN3*del_del_C (OR = 12.54, P = 0.037), and to lepromatous disease/HBV infection: FCN2*TA (OR = 2.5, P = 0.009), whereas FCN2*MAG was associated with increased FCN-2 expression and resistance against coinfection (OR = 0.29, P = 0.026). These associations were independent of demographic factors and did not increase susceptibility to leprosy per se, except MASP2*1C2-l. Associations for FCN2, FCN3, MASP1, MASP2, and VSIG4 variants were also independent of each other. In conclusion, polymorphisms compromising activation of the lectin pathway of complement increase susceptibility to HBV infection, with ficolin polymorphisms playing a major role in modulating the susceptibility among leprosy patients. Frontiers Media S.A. 2021-02-11 /pmc/articles/PMC7904891/ /pubmed/33643280 http://dx.doi.org/10.3389/fimmu.2020.574457 Text en Copyright © 2021 Boldt, Oliveira-Toré, Kretzschmar, Weinschutz Mendes, Stinghen, Andrade, Bumiller-Bini, Gonçalves, Braga, Stahlke, Velavan, Thiel and de Messias-Reason http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Boldt, Angelica Beate Winter Oliveira-Toré, Camila de Freitas Kretzschmar, Gabriela Canalli Weinschutz Mendes, Hellen Stinghen, Sérvio Túlio Andrade, Fabiana Antunes Bumiller-Bini, Valéria Gonçalves, Letícia Boslooper Braga, Anna Carolina de Moraes Stahlke, Ewalda von Rosen Seeling Velavan, Thirumalaisamy P. Thiel, Steffen de Messias-Reason, Iara José Taborda Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors |
title | Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors |
title_full | Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors |
title_fullStr | Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors |
title_full_unstemmed | Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors |
title_short | Hepatitis B Virus Infection Among Leprosy Patients: A Case for Polymorphisms Compromising Activation of the Lectin Pathway and Complement Receptors |
title_sort | hepatitis b virus infection among leprosy patients: a case for polymorphisms compromising activation of the lectin pathway and complement receptors |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904891/ https://www.ncbi.nlm.nih.gov/pubmed/33643280 http://dx.doi.org/10.3389/fimmu.2020.574457 |
work_keys_str_mv | AT boldtangelicabeatewinter hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors AT oliveiratorecamiladefreitas hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors AT kretzschmargabrielacanalli hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors AT weinschutzmendeshellen hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors AT stinghenserviotulio hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors AT andradefabianaantunes hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors AT bumillerbinivaleria hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors AT goncalvesleticiaboslooper hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors AT bragaannacarolinademoraes hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors AT stahlkeewaldavonrosenseeling hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors AT velavanthirumalaisamyp hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors AT thielsteffen hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors AT demessiasreasoniarajosetaborda hepatitisbvirusinfectionamongleprosypatientsacaseforpolymorphismscompromisingactivationofthelectinpathwayandcomplementreceptors |